Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELX/TEZ/IVA effects on cough and physical activity in cystic fibrosis
2021-001628-16Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Percent reduction from baseline in cough frequency. Started Jul 2021; status: completed.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2021-001628-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001628-16.